NCT01102790

Brief Summary

The purpose of this study is to determine the HIT-antibody generation without prior heparin-exposure in patients undergoing orthopedic surgery.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
160

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2010

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2010

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

April 7, 2010

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 13, 2010

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2010

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2010

Completed
Last Updated

April 15, 2010

Status Verified

April 1, 2010

Enrollment Period

5 months

First QC Date

April 7, 2010

Last Update Submit

April 14, 2010

Conditions

Keywords

HIT

Outcome Measures

Primary Outcomes (1)

  • incidence of HIT-antibodies

    between day 5 and day 14 after surgery

Secondary Outcomes (1)

  • thromboembolic events

    up to 21 days after surgery

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients in a primary care clinic undergoing orthopedic surgery without heparin exposure

You may qualify if:

  • Major orthopedic surgery

You may not qualify if:

  • Heparin exposure
  • Infection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

J.W.Goethe University Hospital Frankfurt/M.

Frankfurt am Main, Hesse, 60590, Germany

RECRUITING

Related Publications (3)

  • Schindewolf M, Lindhoff-Last E. Fondaparinux-related thrombocytopenia in a patient with former HIT. Response to Rota et al. (Thromb Haemost 2008; 99: 779-781). Thromb Haemost. 2008 Jul;100(1):168-9; author reply 169-70. doi: 10.1160/TH08-04-0222. No abstract available.

    PMID: 18612559BACKGROUND
  • Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med. 2008 Jul;121(7):632-6. doi: 10.1016/j.amjmed.2008.03.012.

    PMID: 18589060BACKGROUND
  • Jay RM, Warkentin TE. Fatal heparin-induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of 'spontaneous' HIT? J Thromb Haemost. 2008 Sep;6(9):1598-600. doi: 10.1111/j.1538-7836.2008.03040.x. Epub 2008 May 29. No abstract available.

    PMID: 18513213BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

serum citrated blood edta blood

MeSH Terms

Conditions

Thrombosis

Condition Hierarchy (Ancestors)

Embolism and ThrombosisVascular DiseasesCardiovascular Diseases

Study Officials

  • Marc Schindewolf, MD

    J.W. Goethe University-Hospital Frankfurt/M.

    PRINCIPAL INVESTIGATOR
  • Edelgard Lindhoff-Last, Prof.

    J.W. Goethe-University Hospital Frankfurt/M.

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Marc Schindewolf, MD

CONTACT

Edelgard Lindhoff-Last, Prof.

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

April 7, 2010

First Posted

April 13, 2010

Study Start

April 1, 2010

Primary Completion

September 1, 2010

Study Completion

October 1, 2010

Last Updated

April 15, 2010

Record last verified: 2010-04

Locations